Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT01903109

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

Sponsor: Roxane Laboratories

Conditions Dry Mouth

Interventions Cevimeline

Updated 7 times since 2017 Last updated: Jan 19, 2018 Started: Feb 28, 2009 Primary completion: Feb 28, 2009 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01903109, this EARLY_PHASE1 trial focuses on Dry Mouth and remains completed. Sponsored by Roxane Laboratories, it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2018 — Jun 2018 [monthly]

Completed EARLY_PHASE1

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Roxane Laboratories

Data source: West-Ward Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Las Vegas, United States